## Product Datasheet

# CB-839

Catalog No. **BP-01890** · CAS **1439399-58-2** · Form **free base** · Physical state **solid** · Color **Off-white to yellow** · Version **1.0** · Revision **2026-09-04**

**FOR RESEARCH USE ONLY. NOT FOR HUMAN OR VETERINARY USE.**

| Target | Research area |
|---|---|
| **Autophagy; Glutaminase** | **Cancer** |

| | |
|---|---|
| Molecular formula | $C_{26}H_{24}F_3N_7O_3S$ |
| Molecular weight | **571.5740** |

**STRUCTURE**



## DESCRIPTION

Telaglenastat (CB-839) is a first-in-class, reversible and orally bioavailable glutaminase 1 (GLS1) inhibitor. Telaglenastat (CB-839) selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2.

## BIOLOGICAL ACTIVITY

In Vitro

Telaglenastat (CB-839) (0.1-1000 nM; 72 hours) has antiproliferative activity in HCC1806 and MDA-MB-231 cells with IC50s of 49 nM and 26 nM, respectively.

Telaglenastat (CB-839) (1 μM; 72 hours) activates caspase 3/7 and induces apoptosis in MDA-MB-231 and HCC1806 cells.

In Vivo

Telaglenastat (CB-839) (200 mg/kg; p.o.; twice daily for 28 days) has antitumor activity in xenograft models of TNBC.

## SOLUBILITY

Soluble in DMSO

## REFERENCES

[1]. Gross MI, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901.

[2]. Biancur DE, et al. Compensatory metabolic networks in pancreatic cancers upon perturbation of glutaminemetabolism. Nat Commun. 2017 Jul 3;8:15965.

[3]. Zhou WJ, et al. Estrogen inhibits autophagy and promotes growth of endometrial cancer by promoting glutamine metabolism. Cell Commun Signal. 2019 Aug 20;17(1):99.